ArticleThe Journal of infectious diseases2015
Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.Military Medical Research · 2024Review
- Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.International immunopharmacology · 2022Review
- Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates.Antibody therapeutics · 2020Review
- Effect and clinical value of coagulation test on adverse reactions of blood transfusion in patients with major bleeding in ectopic pregnancy.Experimental and therapeutic medicine · 2018Article
- Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Critical reviews in biotechnology · 2017Review
- Engineering Antibodies for the Treatment of Infectious Diseases.Advances in experimental medicine and biology · 2017Review
- Treatment-donation-stockpile dynamics in ebola convalescent blood transfusion therapy.Journal of theoretical biology · 2016Article
- Convalescent plasma: new evidence for an old therapeutic tool?Blood transfusion = Trasfusione del sangue · 2016Review
- Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2016Review
- Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak.Clinical trials (London, England) · 2016Article
- Modeling the transmission dynamics of Ebola virus disease in Liberia.Scientific reports · 2015Article
- A pregnant woman with COVID-19 gives birth to premature triplets: A case report and literature review.Medicine internationalArticle
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundTo combat the 2014-2015 Ebola virus disease (EVD) epidemic in West Africa, the World Health Organization urged the rapid evaluation of convalescent whole blood (CWB) and plasma (CP) transfusion therapy. However, the feasibility and likely impacts of broad implementation of transfusions are yet unknown.
methodsWe extended an Ebola virus transmission model published by the Centers for Disease Control and Prevention to include hospital-based convalescent donations and transfusions. Using recent epidemiological estimates for EVD in Liberia and assuming that convalescent transfusions reduce the case-fatality rate to 12.5% (range, 7.5%-17.5%), we projected the impacts of a countrywide ramp-up of transfusion therapy.
resultsUnder the 10% case-hospitalization rate estimated for Liberia in September 2014, large-scale CP therapy is expected to save 3586 lives by October 2015 (3.1% mortality reduction; 95% confidence interval [CI], .52%-4.5%). Under a higher 30% hospitalization rate, CP transfusions are expected to save 151 lives (0.9% of the total; 95% CI, .21%-11%).
conclusionsTransfusion therapy for EVD is a low-cost measure that can potentially save many lives in West Africa but will not measurably influence the prevalence. Under all scenarios considered, CP transfusions are predicted to achieve greater reductions in mortality than CWB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.